We’ve all seen the headlines, and the message is clear: the nation’s biomedical research sector is facing a massive upheaval. Unprecedented reductions in both funding and the workforce are forcing universities and AMCs to navigate a new reality in which federal funding is reprioritized, competition for that funding is ramped up, and financial pressures threaten program stability.

While the long-term impact of the current administration’s policies remains to be seen, ECG’s Andrea Wetmore and Ryan Moynihan argue that organizations have several opportunities to adapt to the mounting operational and financial challenges. Proactive planning will not only help organizations mitigate this period of acute uncertainty but also ensure they are even more successful when—and if—federal funding rebounds.

Edited by Emily Johnson